| Stereochemistry | RACEMIC |
| Molecular Formula | C21H29NO |
| Molecular Weight | 311.4611 |
| Optical Activity | ( + / - ) |
| Defined Stereocenters | 0 / 1 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
CN(C)CCOC(C1=CC=CC=C1)C2=CC=CC=C2C(C)(C)C
InChI
InChIKey=OGNRRAFRDFGFKA-UHFFFAOYSA-N
InChI=1S/C21H29NO/c1-21(2,3)19-14-10-9-13-18(19)20(23-16-15-22(4)5)17-11-7-6-8-12-17/h6-14,20H,15-16H2,1-5H3
| Molecular Formula | C21H29NO |
| Molecular Weight | 311.4611 |
| Charge | 0 |
| Count |
MOL RATIO
1 MOL RATIO (average) |
| Stereochemistry | RACEMIC |
| Additional Stereochemistry | No |
| Defined Stereocenters | 0 / 1 |
| E/Z Centers | 0 |
| Optical Activity | ( + / - ) |
Bufenadrine is a derivative of diphenhydramine. The compound was originally developed as an anti-motion sickness drug. Prolonged toxicity studies in rats, however, showed liver toxicity, and no further clinical evaluation was undertaken. Investigation of the metabolism showed that (-)-bufenadrine was enantiomer, exclusively responsible for toxic activities of the racemic compound.
Approval Year
PubMed
Patents
|
|
ENANTIOMER -> RACEMATE | |||
|
|
ENANTIOMER -> RACEMATE | |||
|
|
SALT/SOLVATE -> PARENT |
|
Showing 1 to 3 of 3 entries
